Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_curated type ECO_0000205 NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- source_evidence_curated label "DisGeNET evidence - CURATED" NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- source_evidence_curated comment "Gene-disease associations manually curated." NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_assertion wasGeneratedBy ECO_0000218 NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_assertion wasDerivedFrom ctd_human-20130708 NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_assertion SIO_000772 21908430 NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_assertion evidence source_evidence_curated NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- ctd_human-20130708 importedOn "2013-07-24" NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.